GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Intrinsic Value: Projected FCF

Formycon AG (XTER:FYB) Intrinsic Value: Projected FCF : €17.29 (As of May. 16, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-16), Formycon AG's Intrinsic Value: Projected FCF is €17.29. The stock price of Formycon AG is €43.60. Therefore, Formycon AG's Price-to-Intrinsic-Value-Projected-FCF of today is 2.5.

The historical rank and industry rank for Formycon AG's Intrinsic Value: Projected FCF or its related term are showing as below:

XTER:FYB' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2.52   Med: 10.18   Max: 54.13
Current: 2.52

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Formycon AG was 54.13. The lowest was 2.52. And the median was 10.18.

XTER:FYB's Price-to-Projected-FCF is ranked worse than
51.9% of 210 companies
in the Biotechnology industry
Industry Median: 2.48 vs XTER:FYB: 2.52

Formycon AG Intrinsic Value: Projected FCF Historical Data

The historical data trend for Formycon AG's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Intrinsic Value: Projected FCF Chart

Formycon AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 3.74 1.09 13.98 17.29

Formycon AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 - 13.98 - 17.29

Competitive Comparison of Formycon AG's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Formycon AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Formycon AG's Price-to-Projected-FCF falls into.



Formycon AG Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Formycon AG's Free Cash Flow(6 year avg) = €-13.10.

Formycon AG's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-13.096+502.751*0.8)/16.049
=17.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Formycon AG  (XTER:FYB) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Formycon AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=43.60/17.292184902439
=2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Formycon AG Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Formycon AG's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG (XTER:FYB) Business Description

Industry
Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a pharmaceutical company. It is engaged in the development of pharmaceutical and biopharmaceutical products and the development of drug delivery systems. Its focus is on treatments in ophthalmology and immunology as well as other chronic diseases. The company's pipeline in the biosimilar drugs category includes FYB201, FYB202, FYB203, and FYB207 for the treatment of COVID 19. It is also engaged in the provision of diagnostic laboratory services and works for third parties and the carrying out of diagnostic laboratory services.
Executives
Dr. Stefan Glombitza Board of Directors
Dr. Carsten Brockmeyer Board of Directors
Dr. Nicolas Combé Board of Directors

Formycon AG (XTER:FYB) Headlines

No Headlines